All In Biotech

Drug Trial Radar · NCT04543071

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Nov 9, 2020

Primary completion

Jun 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals; BioLine Rx
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells. Cemiplimab is FDA approved for treatment of skin cancer but not for pancreas cancer. Participants will also receive Motixafortide, a new medication which has shown in the laboratory to help immunotherapy work better. Motixafortide has been tested together with immunotherapy (Pembrolizumab), and chemotherapy (5-Fluorouracil and liposomal Irinotecan) and was deemed safe to test additional patients. Motixafortide has not been tested with the specific immunotherapy (Cemiplimab) and chemotherapy (gemcitabine and nab-paclitaxel) which participants will receive and is being tested in this clinical trial.

Conditions

  • Pancreatic Cancer
  • Adenocarcinoma of the Pancreas
  • Adenocarcinoma

Interventions

  • MotixafortideDrug

    1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly

  • CemiplimabDrug

    350 mg intravenous (IV) once every 21 days

  • GemcitabineDrug

    1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)

  • Nab paclitaxelDrug

    125 mg/m2 IV on days 1, 8, 14 (every 28 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (Complete Response (CR) + Partial Response (PR))Time frame: 16 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Columbia University Irving Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Brown University

    Providence, Rhode Island

  • Medical College of Wisconsin, Wisconsin Diagnostic Labratories

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.